120 related articles for article (PubMed ID: 29181171)
1. Subserous invasion of VEGF-C-producing cancer cells is a possible risk factor for ileal ulceration in the non-metastatic mucosal layer during bevacizumab-combined chemotherapy for recurrent ovarian cancer: A case report.
Matsumoto T; Mizumoto Y; Nakade K; Obata T; Matsuoka A; Myojo S; Ono M; Nakamura M; Fujiwara H
Mol Clin Oncol; 2017 Nov; 7(5):820-824. PubMed ID: 29181171
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
[TBL] [Abstract][Full Text] [Related]
3. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin).
Choi YI; Lee SH; Ahn BK; Baek SU; Park SJ; Kim YS; Shin SH
Cancer Res Treat; 2008 Mar; 40(1):33-5. PubMed ID: 19688063
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
5. Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.
Liu SV; Gollard R; Iqbal S
J Clin Pharm Ther; 2012 Oct; 37(5):607-9. PubMed ID: 22432770
[TBL] [Abstract][Full Text] [Related]
6. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Abbrederis K; Kremer M; Schuhmacher C
Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
[TBL] [Abstract][Full Text] [Related]
7. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
8. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer.
Sasaki A; Harano K; Kogawa T; Matsubara N; Naito Y; Hosono A; Mukai H; Yoshino T; Mukohara T
Case Rep Oncol Med; 2020; 2020():7231358. PubMed ID: 32612862
[TBL] [Abstract][Full Text] [Related]
10. [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
Takano M; Kikuchi Y; Kato M; Yoshikawa T; Kita T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1981-4. PubMed ID: 19011357
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
13. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
14. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
15. [Two Cases of Bowel Perforation during Chemotherapy with Bevacizumab to Metastatic Rectal Cancer].
Miyake Y; Ikeda K; Murakami M; Oka Y; Nezu R; Kurokawa E; Kikkawa N
Gan To Kagaku Ryoho; 2015 Dec; 42 Suppl 1():75-8. PubMed ID: 26809419
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and its use in epithelial ovarian cancer.
Matulonis UA
Future Oncol; 2011 Mar; 7(3):365-79. PubMed ID: 21323425
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
Chen J; Smalligan RD; Nadesan S
Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
